Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 586

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 586
---
 | P_III |     | P_III |     | P_III |     | P_III |     | P_III |     | P_III |     |     — |     |     — |     |     — |
| Sales              |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     | Sales |     | Sales |

| Moore Financial Consulting |

Annex E-22

Total Available Markets AstroRx ® According to the Company, the AstroRx ®is for the treatment of all ALS patients, although it is probable that it will be more efficient when given to patients that are in the early stages of the illness. The total available market therefore comprises every case of ALS. We have assumed that the relevant markets for the Company in the first years of sales are as follows: U.S.A, Japan and the five largest European economies (Germany, UK, France, Italy and Spain). In the following table we present the ALS prevalence in these markets:

| Country    |     |  Population |     | Prevalence 
   per 100k |     | Prevalence |
| USA        |     | 345,426,571 |     |       8.63 |     |     29,824 |
| EU_Germany |     |  84,552,242 |     |       6.23 |     |      5,268 |
| EU_France  |     |  66,548,530 |     |       6.23 |     |      4,146 |
| EU_U.K     |     |  69,138,192 |     |       4.03 |     |      2,786 |
| EU_Spain   |     |  47,910,526 |     |       6.89 |     |      3,301 |
|